Merck Bets $400M on Unvalidated KRAS G12D ON-State Mechanism — Clinical Proof Is Everything

Merck Licenses Preclinical KRAS G12D Inhibitor SPR2015 from SciBrunch

Merck has entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the terms, SciBrunch receives an upfront payment of $400 million and is eligible for up to $2.13 billion in total, including development and commercialization milestones. This deal grants Merck worldwide rights to develop, manufacture, and commercialize SPR2015, aiming to enhance and diversify its precision oncology pipeline with a potent inhibitor for a prevalent mutant form of KRAS found in various human cancers. The transaction has closed, and Merck will record a $400 million pre-tax charge in Q3 2026.

• Merck secured exclusive global rights to SPR2015 from SciBrunch Therapeutics, reinforcing its oncology pipeline. The agreement includes an upfront payment of $400 million to SciBrunch, with potential milestone payments bringing the total aggregate value to $2.13 billion. Merck will account for a $400 million pre-tax charge, or approximately $0.13 per share, in its third-quarter 2026 financial results.
• SPR2015 is described as a potent and selective investigational preclinical molecular glue KRAS G12D (ON) inhibitor. It has demonstrated nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining selectivity over KRAS wildtype. Preclinical data presented at the 2026 AACR Annual Meeting also showed compelling antitumor efficacy as a monotherapy in multiple in vivo cell-derived and patient-derived xenograft (CDX/PDX) models.
• The agreement underscores the therapeutic potential of targeting the KRAS pathway, a key factor in tumor cell growth. SPR2015 targets KRAS G12D, one of the most common oncogenic RAS mutations in human tumors, which drives continuous cell proliferation. This collaboration aims to deliver transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors, addressing longstanding unmet medical needs in oncology.

Understanding the Oncogenic Driver: KRAS G12D in Cancer

KRAS G12D is among the most prevalent oncogenic mutations in human adenocarcinomas, arising at codon 12 — one of three hotspot residues (G12, G13, and Q61) — where substitution of glycine for aspartate results in constitutive activation of the RAS pathway independent of upstream growth factor receptor signaling. This persistent, non-growth-factor-dependent activation drives uncontrolled cellular proliferation and is a primary mechanism of carcinogenesis in cancers of the colon, lung, and pancreas. In colorectal cancer specifically, KRAS G12D represents the most common site variation of the KRAS gene in both primary tumors and pulmonary metastases, and KRAS mutations overall are detected in approximately 30–50% of CRC cases. At the metabolic level, cells harboring KRAS G12D — alongside the G12V allele — significantly alter glutamine metabolism and nitrogen recycling through FOXO1-mediated regulation, a mechanism distinct from other G12 alleles and representing a mutant-specific reprogramming of cellular metabolism that contributes to tumor maintenance and growth.

At the signaling level, KRAS G12D operates within the RAS/RAF/MAPK cellular signaling pathway, with downstream effectors including BRAF and MEK. Functional studies in colorectal cancer cell lines demonstrate that KRAS G12D overexpression confers higher proliferation and migration rates, and selective deregulation of extracellular signal-regulated kinase (ERK) and its downstream target ETS transcription factor ELK1 (ELK1) has been observed with specific KRAS G12 mutants. In pancreatic ductal adenocarcinoma (PDAC), where over 40% of patients present with KRAS G12D mutations, the mutation drives carcinogenesis while also reprogramming cancer metabolism — enhancing glycolysis, macropinocytosis, and autophagy — further sustaining tumor progression through metabolic adaptation.

Resistance to targeted suppression of KRAS G12D introduces additional layers of mechanistic complexity. Long-term inhibition of KRAS G12D with the selective inhibitor MRTX1133 in PDAC leads to remodeling of the tumor microenvironment (TME), initially increasing CD11c⁺ cells with T cell infiltration proximal to cancer cells, but ultimately resulting in reversal of these immune responses. This resistance is promoted by CDK8, a multiprotein mediator complex-associated kinase, which imparts immune evasion in part through induction of downstream CXCL2 chemokine secretion and inhibition of FAS expression. Broader resistance mechanisms across KRAS-mutant cancers also include secondary mutations and pathway reactivation, underscoring that the oncogenic program of KRAS G12D extends beyond cell-intrinsic signaling to encompass dynamic interactions with the immune microenvironment.

Addressing the Unmet Need in KRAS G12D-Mutant Cancers

KRAS G12D is among the most prevalent oncogenic KRAS mutations across human cancers, with particular prevalence in pancreatic cancer, yet direct therapeutic targeting of this variant has remained elusive. The structural properties of the KRAS protein — including its lack of an ideal small-molecule binding pocket and its high affinity for cellular guanosine triphosphate (GTP) — render the design of specific small-molecule drugs challenging.

• Structural druggability constraints: The absence of an ideal small-molecule binding pocket in KRAS and its high affinity for cellular GTP have historically made direct inhibition difficult. While the G12C mutation introduced a targetable cysteine amenable to covalent chemistry, the G12D mutation presents a distinct aspartate residue requiring alternative recognition strategies, such as the backbone NH group interaction demonstrated with monobody inhibitors and the small-molecule MTRX1133.

• Selectivity over wild-type and other RAS isoforms: Achieving selectivity for KRAS(G12D) over wild-type KRAS, other oncogenic KRAS mutations, and the G12D mutation in HRAS and NRAS represents a significant design challenge. Crystallographic studies of G12D-selective monobodies reveal that direct recognition of the Asp12 side chain and engagement of H95 — a residue not conserved across RAS isoforms — are critical features underpinning isoform and mutant selectivity.

• Conformational plasticity of the switch II pocket: The S-II pocket, the groove between switch II and the α3 helix, exhibits considerable conformational variability. Monobody studies have captured this pocket in the most widely open form reported to date, illustrating that the pocket's plasticity must be accounted for in inhibitor design and that binding affinity and selectivity are sensitive to the GTP- versus GDP-bound state of KRAS(G12D).

• Immunosuppressive tumor microenvironment in KRAS G12D-driven cancers: In pancreatic ductal adenocarcinoma — where KRAS G12D mutations are highly prevalent — KRAS mutations contribute directly to low tumor immunogenicity and an immunosuppressive tumor microenvironment (TME). This TME is enriched with regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and is further reinforced by physical barriers including cancer-associated fibroblasts (CAFs), aberrant vasculature, and excessive hyaluronic acid deposition, collectively limiting the efficacy of both immunotherapy and targeted agents.

• Limited systemic treatment efficacy in KRAS G12D-associated PDAC: In advanced pancreatic ductal adenocarcinoma, current standard-of-care combination chemotherapy regimens — FOLFIRINOX and gemcitabine/nab-paclitaxel — yield modest clinical benefit, with median progression-free survival upon first palliative chemotherapy of 4.1 months. Second-line regimens produce similar PFS outcomes regardless of regimen (overall median PFS 2.3 months), underscoring the urgent need for more effective targeted approaches in this KRAS G12D-enriched disease.

Merck's Strategic Leap into the KRAS G12D Frontier

The acquisition of SPR2015 by Merck represents a bold strategic maneuver into one of oncology's most challenging frontiers: directly targeting the KRAS G12D mutation. This specific mutation is a pervasive oncogenic driver, particularly in pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer, where it has historically been deemed 'undruggable' due to its unique structural characteristics and high affinity for GTP. The scientific community has made significant strides in recent years, moving beyond this perception by developing innovative small-molecule inhibitors. These include compounds that exploit dynamic allosteric pockets within the KRAS protein or, crucially, tri-complex inhibitors that bind the active, GTP-bound 'ON' state of RAS to block oncogenic signaling. SPR2015, described as a KRAS G12D (ON) inhibitor, aligns with these cutting-edge approaches, suggesting a mechanism designed to overcome previous therapeutic hurdles.

However, this promising venture is not without its inherent risks. As a preclinical asset, SPR2015 faces the formidable challenge of navigating the rigorous and often unpredictable path of clinical development, where many promising candidates fail to demonstrate sufficient efficacy or acceptable safety profiles. Furthermore, the literature consistently highlights the critical issue of acquired resistance in RAS-driven malignancies. Patients treated with RAS inhibitors can develop resistance through secondary mutations in RAS itself or by activating bypass signaling pathways, which could necessitate the rapid development of combination therapies to maintain long-term clinical benefit. The competitive landscape for KRAS G12D inhibitors is also rapidly evolving, with various modalities and mechanisms under investigation. Merck's success will depend on SPR2015's ability to demonstrate a differentiated profile and superior efficacy compared to other emerging therapies. This strategic investment, while high-risk, underscores the immense potential rewards of delivering an effective therapy for a mutation that impacts millions of cancer patients globally, potentially reshaping the standard of care in several major cancer types.